President Kim Kyung-ah of Samsung Epis Holdings held a press briefing on the 14th at the JP Morgan Healthcare Conference in ...

Early-stage regulatory strategy is becoming a powerful driver of speed, risk reduction, and commercial value in drug ...

The FDA has proposed new policies to speed up the development and lower the cost of biosimilar agents for cancer and other serious illnesses. These policies include “major updates to simplify ...

Two formative experiences shaped Craig Crews’ path into drug development. First, when he was still a child, his grandmother died from cancer at just 52 years old. “At the time, there weren’t very many ...

The proposed federal budget would see drastic cuts made to most of the agencies that fund science. The sheer magnitude of the cuts—including a 40 percent slashing of money going to the National ...

In 2021, Malachite initiated a corporate restructuring plan to create two parallel pathways for shareholder value creation and optimize the present value of its more than $20 million of net operating ...

Rallybio has agreed to sell its interest in a drug-development plan seeking to treat a rare genetic bone disease to its joint-venture partner Recursion Pharmaceuticals for up to $25 million. The New ...